China Sky One Medical Shifts Focus to Antibiotics and Cardiac Drugs
China Sky One Medical, Inc., a leading pharmaceutical company, announced a strategic shift in its subsidiary Heilongjiang Tianlong Pharmaceutical Company's (Tianlong) research and development (R&D) focus from external use medicines to antibiotics and cardiac drugs. This move aims to capitalize on the growing demand for prescription drugs in China, driven by expanding medical insurance coverage. Tianlong's R&D portfolio now targets key market segments, including antibiotics, which account for 20%-25% of total sales of western medicines in China.
Key Takeaways:
- China Sky One Medical's subsidiary Tianlong will focus on developing antibiotics and cardiac drugs to capitalize on the growing demand for prescription drugs in China.
- Tianlong possesses the most complete portfolio of external use medicines in China and aims to leverage its expertise in developing new drugs.
- The Company plans to introduce five new antibiotics and two cardiac drugs, after completing feasibility analysis and mastering production technology.
- China Sky One Medical expects to strengthen its distribution channel for prescription drugs by engaging more qualified commercial medical companies.
- The Company's CEO, Mr. Yan-Qing Liu, emphasizes the opportunity to capitalize on China's fragmented pharmaceutical industry and meet the growing demand for better healthcare services.
- The new focus on antibiotics and cardiac drugs is expected to drive the Company's future growth.
Statistics:
- Antibiotics account for 20%-25% of total sales of western medicines in China.
- Cardiac diseases represent the third largest drug category in China, accounting for roughly 15% of total sales of chemical medicines.
- China Sky One Medical plans to introduce five new antibiotics and two cardiac drugs.
- The Company has completed a feasibility analysis and mastered production technology for the new drugs.
Sources:
- China Sky One Medical, Inc.
- China Sky One Medical, Inc. via NewsRx.com